Role of place of acquisition and inappropriate empirical antibiotic therapy on the outcome of extended-spectrum β-lactamase-producing Enterobacteriaceae infections

Evelina Tacconelli, Maria Adriana Cataldo, Nico T. Mutters, Elena Carrara, Alessandro Bartoloni, Annibale Raglio, Roberto Cauda, Elisabetta Mantengoli, Francesco Luzzaro, Angelo Pan, Lia A. Beccara, Patrizia Pecile, Marco Tinelli, Gian Maria Rossolini

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The impact of inappropriate empirical antibiotic therapy (IEAT)on the outcome of severe infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-Ent)remains unclear. Current evidence is limited by study design and lack of confounder control. The main objective of this study was to define the outcome of severe infections due to ESBL-Ent according to clinical parameters and place of infection acquisition. Adult hospitalised patients with ESBL-Ent infections were included in a 3-year multicentre prospective study. Primary outcomes were IEAT rates and crude mortality of severe infections, adjusted by place of acquisition [community-acquired infection (CAI), healthcare-associated infection (HCAI)and hospital-acquired infection (HAI)]. Among 729 patients, 519 (71.2%)were diagnosed with HAI, 176 (24.1%)with HCAI and 34 (4.7%)with CAI. Moreover, 32.9% of patients received IEAT; higher rates of IEAT were observed in pneumonia (23%)and deep surgical site infections (19%). HCAIs were more frequently associated with IEAT than HAIs (48.3% vs. 27.9%; OR = 1.7, 95% CI 1.2–2.4). The overall mortality rate for severe infections (n = 264)was 12.1% and was significantly higher in HCAIs (20%)than HAIs (10%)(RR = 2.3, 95% CI 1.01–5.3). IEAT significantly increased the risk of mortality in bloodstream infections (RR = 8.3, 95% CI 2–46.3). Rates of IEAT and overall mortality of ESBL-Ent severe infections were higher in HCAIs than HAIs. Prompt diagnosis of patients with severe HCAIs due to ESBL-Ent is essential since these infections receive high rates of IEAT and significantly higher mortality than HAIs [ClinicalTrials.gov Identifier: NCT00404625].

Original languageEnglish
Pages (from-to)1-6
JournalInternational Journal of Antimicrobial Agents
DOIs
Publication statusE-pub ahead of print - Apr 12 2019

Fingerprint

Enterobacteriaceae Infections
Anti-Bacterial Agents
Infection
Cross Infection
Mortality
Community-Acquired Infections
Therapeutics
Surgical Wound Infection
Enterobacteriaceae
Multicenter Studies
Pneumonia

Keywords

  • Community-acquired infection
  • ESBL
  • Extended-spectrum β-lactamase
  • Inappropriate antibiotic therapy

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Role of place of acquisition and inappropriate empirical antibiotic therapy on the outcome of extended-spectrum β-lactamase-producing Enterobacteriaceae infections. / Tacconelli, Evelina; Cataldo, Maria Adriana; Mutters, Nico T.; Carrara, Elena; Bartoloni, Alessandro; Raglio, Annibale; Cauda, Roberto; Mantengoli, Elisabetta; Luzzaro, Francesco; Pan, Angelo; Beccara, Lia A.; Pecile, Patrizia; Tinelli, Marco; Rossolini, Gian Maria.

In: International Journal of Antimicrobial Agents, 12.04.2019, p. 1-6.

Research output: Contribution to journalArticle

Tacconelli, Evelina ; Cataldo, Maria Adriana ; Mutters, Nico T. ; Carrara, Elena ; Bartoloni, Alessandro ; Raglio, Annibale ; Cauda, Roberto ; Mantengoli, Elisabetta ; Luzzaro, Francesco ; Pan, Angelo ; Beccara, Lia A. ; Pecile, Patrizia ; Tinelli, Marco ; Rossolini, Gian Maria. / Role of place of acquisition and inappropriate empirical antibiotic therapy on the outcome of extended-spectrum β-lactamase-producing Enterobacteriaceae infections. In: International Journal of Antimicrobial Agents. 2019 ; pp. 1-6.
@article{cc9a37751fc745a0b9ebb06b6217bb86,
title = "Role of place of acquisition and inappropriate empirical antibiotic therapy on the outcome of extended-spectrum β-lactamase-producing Enterobacteriaceae infections",
abstract = "The impact of inappropriate empirical antibiotic therapy (IEAT)on the outcome of severe infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-Ent)remains unclear. Current evidence is limited by study design and lack of confounder control. The main objective of this study was to define the outcome of severe infections due to ESBL-Ent according to clinical parameters and place of infection acquisition. Adult hospitalised patients with ESBL-Ent infections were included in a 3-year multicentre prospective study. Primary outcomes were IEAT rates and crude mortality of severe infections, adjusted by place of acquisition [community-acquired infection (CAI), healthcare-associated infection (HCAI)and hospital-acquired infection (HAI)]. Among 729 patients, 519 (71.2{\%})were diagnosed with HAI, 176 (24.1{\%})with HCAI and 34 (4.7{\%})with CAI. Moreover, 32.9{\%} of patients received IEAT; higher rates of IEAT were observed in pneumonia (23{\%})and deep surgical site infections (19{\%}). HCAIs were more frequently associated with IEAT than HAIs (48.3{\%} vs. 27.9{\%}; OR = 1.7, 95{\%} CI 1.2–2.4). The overall mortality rate for severe infections (n = 264)was 12.1{\%} and was significantly higher in HCAIs (20{\%})than HAIs (10{\%})(RR = 2.3, 95{\%} CI 1.01–5.3). IEAT significantly increased the risk of mortality in bloodstream infections (RR = 8.3, 95{\%} CI 2–46.3). Rates of IEAT and overall mortality of ESBL-Ent severe infections were higher in HCAIs than HAIs. Prompt diagnosis of patients with severe HCAIs due to ESBL-Ent is essential since these infections receive high rates of IEAT and significantly higher mortality than HAIs [ClinicalTrials.gov Identifier: NCT00404625].",
keywords = "Community-acquired infection, ESBL, Extended-spectrum β-lactamase, Inappropriate antibiotic therapy",
author = "Evelina Tacconelli and Cataldo, {Maria Adriana} and Mutters, {Nico T.} and Elena Carrara and Alessandro Bartoloni and Annibale Raglio and Roberto Cauda and Elisabetta Mantengoli and Francesco Luzzaro and Angelo Pan and Beccara, {Lia A.} and Patrizia Pecile and Marco Tinelli and Rossolini, {Gian Maria}",
year = "2019",
month = "4",
day = "12",
doi = "10.1016/j.ijantimicag.2019.04.007",
language = "English",
pages = "1--6",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",

}

TY - JOUR

T1 - Role of place of acquisition and inappropriate empirical antibiotic therapy on the outcome of extended-spectrum β-lactamase-producing Enterobacteriaceae infections

AU - Tacconelli, Evelina

AU - Cataldo, Maria Adriana

AU - Mutters, Nico T.

AU - Carrara, Elena

AU - Bartoloni, Alessandro

AU - Raglio, Annibale

AU - Cauda, Roberto

AU - Mantengoli, Elisabetta

AU - Luzzaro, Francesco

AU - Pan, Angelo

AU - Beccara, Lia A.

AU - Pecile, Patrizia

AU - Tinelli, Marco

AU - Rossolini, Gian Maria

PY - 2019/4/12

Y1 - 2019/4/12

N2 - The impact of inappropriate empirical antibiotic therapy (IEAT)on the outcome of severe infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-Ent)remains unclear. Current evidence is limited by study design and lack of confounder control. The main objective of this study was to define the outcome of severe infections due to ESBL-Ent according to clinical parameters and place of infection acquisition. Adult hospitalised patients with ESBL-Ent infections were included in a 3-year multicentre prospective study. Primary outcomes were IEAT rates and crude mortality of severe infections, adjusted by place of acquisition [community-acquired infection (CAI), healthcare-associated infection (HCAI)and hospital-acquired infection (HAI)]. Among 729 patients, 519 (71.2%)were diagnosed with HAI, 176 (24.1%)with HCAI and 34 (4.7%)with CAI. Moreover, 32.9% of patients received IEAT; higher rates of IEAT were observed in pneumonia (23%)and deep surgical site infections (19%). HCAIs were more frequently associated with IEAT than HAIs (48.3% vs. 27.9%; OR = 1.7, 95% CI 1.2–2.4). The overall mortality rate for severe infections (n = 264)was 12.1% and was significantly higher in HCAIs (20%)than HAIs (10%)(RR = 2.3, 95% CI 1.01–5.3). IEAT significantly increased the risk of mortality in bloodstream infections (RR = 8.3, 95% CI 2–46.3). Rates of IEAT and overall mortality of ESBL-Ent severe infections were higher in HCAIs than HAIs. Prompt diagnosis of patients with severe HCAIs due to ESBL-Ent is essential since these infections receive high rates of IEAT and significantly higher mortality than HAIs [ClinicalTrials.gov Identifier: NCT00404625].

AB - The impact of inappropriate empirical antibiotic therapy (IEAT)on the outcome of severe infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-Ent)remains unclear. Current evidence is limited by study design and lack of confounder control. The main objective of this study was to define the outcome of severe infections due to ESBL-Ent according to clinical parameters and place of infection acquisition. Adult hospitalised patients with ESBL-Ent infections were included in a 3-year multicentre prospective study. Primary outcomes were IEAT rates and crude mortality of severe infections, adjusted by place of acquisition [community-acquired infection (CAI), healthcare-associated infection (HCAI)and hospital-acquired infection (HAI)]. Among 729 patients, 519 (71.2%)were diagnosed with HAI, 176 (24.1%)with HCAI and 34 (4.7%)with CAI. Moreover, 32.9% of patients received IEAT; higher rates of IEAT were observed in pneumonia (23%)and deep surgical site infections (19%). HCAIs were more frequently associated with IEAT than HAIs (48.3% vs. 27.9%; OR = 1.7, 95% CI 1.2–2.4). The overall mortality rate for severe infections (n = 264)was 12.1% and was significantly higher in HCAIs (20%)than HAIs (10%)(RR = 2.3, 95% CI 1.01–5.3). IEAT significantly increased the risk of mortality in bloodstream infections (RR = 8.3, 95% CI 2–46.3). Rates of IEAT and overall mortality of ESBL-Ent severe infections were higher in HCAIs than HAIs. Prompt diagnosis of patients with severe HCAIs due to ESBL-Ent is essential since these infections receive high rates of IEAT and significantly higher mortality than HAIs [ClinicalTrials.gov Identifier: NCT00404625].

KW - Community-acquired infection

KW - ESBL

KW - Extended-spectrum β-lactamase

KW - Inappropriate antibiotic therapy

UR - http://www.scopus.com/inward/record.url?scp=85066121317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066121317&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2019.04.007

DO - 10.1016/j.ijantimicag.2019.04.007

M3 - Article

C2 - 30986523

AN - SCOPUS:85066121317

SP - 1

EP - 6

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

ER -